Industry experts discuss the current state of the immune category, emerging research to note, and a look at what’s to come as ...
AllAfrica on MSN
WHO Approves First Child-Friendly Malaria Drug - a Major Boost for Malawi's Fight Against the Killer Disease
Malawi's war against malaria has received a powerful new weapon following the World Health Organization's approval of the first-ever child-friendly, transmission-blocking formulations of ...
Tribune Online on MSN
WHO approves first child-friendly primaquine to treat malaria relapse
WHO has approved the first-ever paediatric primaquine tablets for malaria treatment, a breakthrough moment for malaria elimination.Developed by Medicines for Malaria Venture (MMV) and Fosun Pharma ...
Positive results mark an important step forward in efforts to develop effective treatments for children with drug-resistant TB COPENHAGEN, Denmark, Nov. 19, 2025 /PRNewswire/ -- New interim data from ...
PwdRx novel drug delivery platform demonstrated superior bioavailability and accelerated absorption of cannabinoids in ...
Valued at USD 4.6 billion in 2025, the market is projected to reach USD 8.2 billion by 2035, reflecting a steady 5.9% CAGR. Sorbitol remains the highest-volume segment with a 25% revenue share, while ...
PRNewswire/ - Medunik USA, a specialty pharmaceutical company, and part of Duchesnay Pharmaceutical Group (DPG), is dedicated to providing patients with rare diseases access to orphan drugs. Medunik ...
Harrow has completed the acquisition of Melt Pharmaceuticals, which includes product candidates MELT-210, MELT-300, and ...
TONMYA is now available by prescription and available for pharmacy ordering nationwideTONMYA is the first FDA-approved treatment for fibromyalgia ...
Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptide and protein replacement therapies, today reported ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback